Mobilizing data during a crisis: Building rapid evidence pipelines using multi-institutional real world data.

COVID-19 Consortia Pandemic response Rapid evidence generation Real world data

Journal

Healthcare (Amsterdam, Netherlands)
ISSN: 2213-0772
Titre abrégé: Healthc (Amst)
Pays: Netherlands
ID NLM: 101622189

Informations de publication

Date de publication:
25 Mar 2024
Historique:
received: 10 05 2023
revised: 05 09 2023
accepted: 22 02 2024
medline: 27 3 2024
pubmed: 27 3 2024
entrez: 26 3 2024
Statut: aheadofprint

Résumé

The COVID-19 pandemic generated tremendous interest in using real world data (RWD). Many consortia across the public and private sectors formed in 2020 with the goal of rapidly producing high-quality evidence from RWD to guide medical decision-making, public health priorities, and more. Experiences were gathered from five large consortia on rapid multi-institutional evidence generation during the COVID-19 pandemic. Insights have been compiled across five dimensions: consortium composition, governance structure and alignment of priorities, data sharing, data analysis, and evidence dissemination. The purpose of this piece is to offer guidance on building large-scale multi-institutional RWD analysis pipelines for future public health issues. The composition of each consortium was largely influenced by existing collaborations. A central set of priorities for evidence generation guided each consortium, however different approaches to governance emerged. Challenges surrounding limited access to clinical data due to various contributors were overcome in unique ways. While all consortia used different methods to construct and analyze patient cohorts ranging from centralized to federated approaches, all proved effective for generating meaningful real-world evidence. Actionable recommendations for clinical practice and public health agencies were made from translating insights from consortium analyses. Each consortium was successful in rapidly answering questions about COVID-19 diagnosis and treatment despite all taking slightly different approaches to data sharing and analysis. Leveraging RWD, leveraged in a manner that applies scientific rigor and transparency, can complement higher-level evidence and serve as an important adjunct to clinical trials to quickly guide policy and critical care, especially for a pandemic response.

Identifiants

pubmed: 38531228
pii: S2213-0764(24)00005-8
doi: 10.1016/j.hjdsi.2024.100738
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100738

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jayson S Marwaha (JS)

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Maren Downing (M)

Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA; Campbell University School of Osteopathic Medicine, Lillington, NC, USA.

John Halamka (J)

Mayo Clinic Platform, USA.

Amy Abernethy (A)

Verily Life Sciences LLC, USA.

Joseph B Franklin (JB)

Verily Life Sciences LLC, USA.

Brian Anderson (B)

The MITRE Corporation, USA.

Isaac Kohane (I)

Harvard Medical School, USA.

Kavishwar Wagholikar (K)

Harvard Medical School, USA.

John Brownstein (J)

Harvard Medical School, USA.

Melissa Haendel (M)

University of Colorado Anschutz Medical Campus School of Medicine, USA.

Gabriel A Brat (GA)

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. Electronic address: gbrat@bidmc.harvard.edu.

Classifications MeSH